biotech Open-Science Consortium Peer-reviewed literature • Clinical trial tracking • Translational research audit for Limb-Girdle Muscular Dystrophy R4 (LGMD2E).
β
SGCBResearch LGMD R4
menu_book Literature
verified Open-Science Translational Biology • Global Research Hub

Precision Therapeutics for β-Sarcoglycanopathy

The central scientific repository for Limb-Girdle Muscular Dystrophy R4 (LGMD 2E / SGCB deficiency): connecting human clinical genetics, AAV clinical pipelines, in vivo base editing, and cytoprotective peptide biophysics.

vaccines Gene Therapy & CRISPR shield 4-Layer Peptide Shield radar Live Research Radar
Abstract 3D molecular visualization of the human sarcoglycan complex spanning a lipid bilayer
biotech Cryo-EM / Structural Model
Molecular Architecture NM_000232.5
Transmembrane Sarcoglycan Core Tetramer
Stoichiometric assembly (α, β, γ, δ) anchoring the dystrophin-glycoprotein complex and dissipating contractile shear strain.
info

Patient & Clinical Community Transparency Charter

Limb-Girdle Muscular Dystrophy R4 (LGMD 2E) is a progressive, life-altering autosomal recessive disease. Families navigating this diagnosis deserve absolute scientific truth, rigorous peer-reviewed evidence, and an unvarnished assessment of translational realities:

warning Regulatory Reality
There are currently no FDA, EMA, or TGA-approved disease-modifying or curative treatments for LGMD R4. Standard of care remains supportive multidisciplinary management, physical therapy avoiding eccentric strain, and proactive cardiac/respiratory surveillance.
biotech AAV Gene Therapy Status
Investigational SRP-9003 (AAVrh74.MHCK7.hSGCB) demonstrated robust protein expression in Phase 1/2 (PMID: 38177855; NCT03652259) and Phase 3 EMERGENE (NCT06246513), but was placed under an FDA clinical hold / pipeline pause in July 2025 due to AAVrh74 vector-class liver safety reviews.
shield Conceptual Peptide Hypotheses
While downstream pathways (P188 membrane sealing, NBD NF-κB blockade, calpastatin, SS-31) are studied in peer-reviewed literature, the specific modified peptide sequences in our AI synthesis dossier are unvalidated in silico concepts—never tested in animals or humans and not for clinical use.

*Disclaimer: This repository is an AI-assisted open-science literature synthesis and theoretical research hub. It does not constitute medical advice, clinical validation, or a treatment protocol. Always consult qualified neuromuscular specialists and clinical geneticists.

apps Platform Architecture

Explore the 6 Research Modules

Navigate into specialized deep-dive sections covering molecular genetics, gene therapy pipelines, custom peptide specifications, and live scientific intelligence.

dna

Molecular Pathology & Genetics

The "House of Cards" sarcoglycan assembly hierarchy, ERAD degradation, and exact molecular analysis of the compound heterozygous Ser114Phe and Tyr184* variants.

View Genetic Mapping arrow_forward
biotech

Gene Therapy & CRISPR Horizons

SRP-9003 Phase 3 EMERGENE biopsy data, AAVrh74 vector biology, in vivo Adenine Base Editing (ABE) for Ser114Phe, and non-viral SORT LNPs / eVLPs.

View Gene Therapy & Editing arrow_forward
shield

Downstream Cytoprotection Audit

Peer-reviewed analysis of membrane sealants (P188), NF-κB blockade (NBD), calpastatin, and SS-31 versus unvalidated in silico peptide concepts.

View Evidence vs. Hypothesis Audit arrow_forward
clinical_notes

Clinical Protocol & Biomarkers

Quantitative 5-tier biomarker matrix: Serum CK, Cardiac MRI (T1/ECV), hs-cTnI, TGF-β1, urinary β2-microglobulin, and NSAA motor batteries.

View Monitoring Framework arrow_forward
radar

Live Research Radar & News

Real-time scientific news feeds connecting to live NCBI PubMed papers, active ClinicalTrials.gov registries, and curated deep-dive clinical reports.

Open Live Radar Feed arrow_forward
description

Dossiers & Literature

Download the complete 4-page Clinical Dossier (MED-SGCB-2026-CLIN) and benchmark report (BIO-DMD-2026-TR8), plus 14 verified PubMed citations.

Download Technical PDFs arrow_forward
view_timeline Development Hierarchy

The 4-Tier Translational Spectrum

Grounding scientific hope in measurable biological realities: how clinical supportive care, AAV gene replacement, precision base editing, and cytoprotective shields intersect.

Tier 1 • Active Standard
Clinical Supportive Care
Non-eccentric physical therapy, annual cardiac MRI with LGE, early ACEi/ARBs for heart strain, and nocturnal respiratory surveillance.
View Protocol arrow_forward
Tier 2 • Clinical Trials (On Hold)
AAV Gene Replacement
SRP-9003 Phase 1/2 (PMID: 38177855) and Phase 3 EMERGENE (NCT06246513) met Day-60 expression endpoints (+43.4% / +23.9% PPF); currently under a July 2025 FDA clinical hold / pipeline pause pending AAVrh74 liver safety review.
View Gene Therapy arrow_forward
Tier 3 • Pre-Clinical / Lab
CFTR Correctors & Base/Prime Editing
CFTR corrector C17 rescued missense β-SG in primary patient myotubes (Scano et al. 2024, PMID: 39769077). Adenine Base Editing (c.341C>T) and Prime Editing (c.552T>G TAG stop) remain theoretical/preclinical with no active SGCB trials.
View Editing & Correctors arrow_forward
Tier 4 • Theoretical Concept
Downstream Cytoprotective Hypotheses
Audit of peer-reviewed cytoprotective pathways (P188 copolymers, NBD peptides, calpastatin, SS-31) vs. unvalidated AI-generated in silico peptide concepts (TRL 1; not tested in animals or humans).
View Scientific Audit arrow_forward
terminal Technical Documentation

Explore the Verified PubMed Bibliography & Conceptual Dossiers

Access 14 peer-reviewed PubMed studies covering SGCB genetics, AAVrh74 trials, and CFTR corrector C17 rescue, alongside our scientific audit of the AI-generated conceptual synthesis drafts.

menu_book View Verified Bibliography fact_check Read Scientific Audit